Table 1.
EC50 values and CI intervals for Urelumab, Utomilumab and Varlilumab.
| Mab | Fc Receptor | EC50 ng/ml | 95% CI |
|---|---|---|---|
| Urelumab | None | 155.3 | 84.84 - 284.3 |
| CD32A | 104.5 | 53.14 - 205.5 | |
| CD32B | 66.12 | 37.74 - 115.8 | |
| CD64 | 119.8 | 52.41 - 273.8 | |
| Utomilumab | CD32A | 196.4 | 47.52 - 812.2 |
| CD32B | 172.2 | 78.51 - 377.5 | |
| Varlilumab | CD16A | 249.2 | 149.4 - 415.5 |
| CD16A F176V | 90.89 | 79.39 - 104.1 | |
| CD32A | 157.5 | 116.5 - 212.8 | |
| CD32B | 27.66 | 23.47 - 32.59 | |
| CD64 | 14.56 | 8.642 - 24.52 |
EC50 values and the 95% confidence intervals (CI) were determined for Urelumab, Utomilumab, and Varlilumab for their ability to induce 41BB-NFκB or CD27-NFκB signaling respectively in a functional assay. Data from three independent experiments performed in duplicates were used to calculate the EC50 values.